IDiyas

For the Inventor, By the Inventor

Troy, MI, United States of America

Josefino B Tunac

USPTO Granted Patents = 11

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 55(Granted Patents)


Company Filing History:

goldMedal11 out of 2,538 
 
Warner-lambert Company
 patents

Years Active: 1985-1990

Loading Chart...
11 patents (USPTO):Explore Patents
1. 4918100 - CL-1957B antibiotic compound and its production (1990-04-17),
2. 4771070 - CL-1957A antibiotic compound (1988-09-13),
3. 4738929 - Purified culture of streptomyces galanosa (1988-04-19),
4. 4734370 - Antibiotic-producing microorganism culture (1988-03-29),
5. 4713372 - 2-chloropentostatin compound having adenosine diaminase inhibitory (1987-12-15),
6. 4657909 - Antimicrobial and antitumor phenazine carboxaldehydes and derivatives (1987-04-14),
7. 4615975 - Purified culture of Actinomadura verrucaspora subspecies veractimyces (1986-10-07),
8. 4578383 - CL 1565 antibiotic compounds (1986-03-25),
9. 4554162 - CL-1724 Antibiotic compounds, their production and use (1985-11-19),
10. 4530835 - CL-1577 Antibiotic compounds and their production (1985-07-23),
11. 4495286 - Antibiotic complex producing bacterial culture (1985-01-22),

Title: The Innovative Contributions of Josefino B Tunac

Introduction

Josefino B Tunac is a notable inventor based in Troy, MI, who has made significant contributions to the field of antibiotic compounds. With a total of 11 patents to his name, Tunac's work focuses on the development of antimicrobial agents that also exhibit antitumor properties. His innovative approach has the potential to impact the medical field significantly.

Latest Patents

Among his latest patents are the CL-1957B and CL-1957A antibiotic compounds. The CL-1957B antibiotic compound is derived from a purified isolate of an actinomycete identified as ATCC 39366. This compound is capable of producing an anti-microbial agent that also shows antitumor properties. The production process involves cultivating isolate ATCC 39366 under aerobic conditions in a culture medium rich in assimilable sources of carbon and nitrogen. Once a substantial quantity of the CL-1957B compound is produced, it is subsequently isolated for use. The patent also covers the pharmaceutical compositions that include this compound, along with methods for treating microbial infections and tumors in mammals.

Similarly, the CL-1957A antibiotic compound is produced using the same isolate, ATCC 39366, under similar conditions. This compound also demonstrates antimicrobial and antitumor properties. The patent details the production process, isolation, and pharmaceutical applications of CL-1957A, providing methods for treating infections and tumors in mammals.

Career Highlights

Josefino B Tunac is currently associated with Warner-Lambert Company, where he continues to innovate in the field of pharmaceuticals. His work has garnered attention for its potential applications in treating serious health conditions.

Collaborations

Throughout his career, Tunac has collaborated with notable colleagues, including James C French and Gerard C Hokanson. These collaborations have likely contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Josefino B Tunac's contributions to antibiotic research and development highlight the importance of innovation in the medical field. His patents, particularly the CL-1957B and CL-1957A compounds, showcase his commitment to creating effective treatments for microbial infections and tumors. His work continues to pave the way for future advancements in pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…